地高辛与比索洛尔控制房颤心室率对患者报告生活质量的影响:RATE-AF随机临床试验
RATE-AF随机开放标签盲法终点试验纳入160例60岁以上永久性房颤伴心力衰竭症状患者,比较低剂量地高辛与比索洛尔。6个月时SF-36躯体成分评分无显著差异,但地高辛组改良EHRA症状分级改善更明显且不良事件更少。
要点
- 低剂量地高辛与比索洛尔在6个月生活质量上无显著差异。
- 地高辛组改良EHRA症状2级改善比例更高(53% vs 9%)。
- 地高辛组不良事件更少(25% vs 64%)。
核心结论
- 在永久性房颤伴心力衰竭症状患者中,低剂量地高辛与比索洛尔在6个月生活质量上无统计学显著差异。
- 这些发现支持可能基于其他终点来制定治疗决策。
研究设计与样本
- 随机、开放标签、盲法终点临床试验,纳入160例60岁及以上永久性房颤且NYHA心功能II级或以上呼吸困难患者。
- 患者来自英国3家医院和初级保健机构,2016年至2018年招募,末次随访2019年10月。
- 地高辛组80例(剂量范围62.5-250 μg/d,平均161 μg/d),比索洛尔组80例(剂量范围1.25-15 mg/d,平均3.2 mg/d)。
临床怎么用
- 对于永久性房颤伴心力衰竭症状的老年患者,低剂量地高辛与比索洛尔均可作为心率控制选择。
- 地高辛可能改善症状分级并减少不良事件,但生活质量主要终点无显著差异。
- 治疗决策可综合考虑症状改善、不良事件及12个月NT-proBNP等次要终点。
局限性
- 开放标签设计,尽管终点评估采用盲法。
- 样本量160例,可能不足以检测生活质量的小差异。
- 仅纳入60岁及以上永久性房颤伴心力衰竭症状患者,结果外推受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: There is little evidence to support selection of heart rate control therapy in patients with permanent atrial fibrillation, in particular those with coexisting heart failure. OBJECTIVE: To compare low-dose digoxin with bisoprolol (a β-blocker). DESIGN, SETTING, AND PARTICIPANTS: Randomized, open-label, blinded end-point clinical trial including 160 patients aged 60 years or older with permanent atrial fibrillation (defined as no plan to restore sinus rhythm) and dyspnea classified as New York Heart Association class II or higher. Patients were recruited from 3 hospitals and primary care practices in England from 2016 through 2018; last follow-up occurred in October 2019. INTERVENTIONS: Digoxin (n = 80; dose range, 62.5-250 μg/d; mean dose, 161 μg/d) or bisoprolol (n = 80; dose range, 1.25-15 mg/d; mean dose, 3.2 mg/d). MAIN OUTCOMES AND MEASURES: The primary end point was patient-reported quality of life using the 36-Item Short Form Health Survey physical component summary score (SF-36 PCS) at 6 months (higher scores are better; range, 0-100), with a minimal clinically important difference of 0.5 SD. There were 17 secondary end points (including resting heart rate, modified European Heart Rhythm Association [EHRA] symptom classification, and N-terminal pro-brain natriuretic peptide [NT-proBNP] level) at 6 months, 20 end points at 12 months, and adverse event (AE) reporting. RESULTS: Among 160 patients (mean age, 76 [SD, 8] years; 74 [46%] women; mean baseline heart rate, 100/min [SD, 18/min]), 145 (91%) completed the trial and 150 (94%) were included in the analysis for the primary outcome. There was no significant difference in the primary outcome of normalized SF-36 PCS at 6 months (mean, 31.9 [SD, 11.7] for digoxin vs 29.7 [11.4] for bisoprolol; adjusted mean difference, 1.4 [95% CI, -1.1 to 3.8]; P = .28). Of the 17 secondary outcomes at 6 months, there were no significant between-group differences for 16 outcomes, including resting heart rate (a mean of 76.9/min [SD, 12.1/min] with digoxin vs a mean of 74.8/min [SD, 11.6/min] with bisoprolol; difference, 1.5/min [95% CI, -2.0 to 5.1/min]; P = .40). The modified EHRA class was significantly different between groups at 6 months; 53% of patients in the digoxin group reported a 2-class improvement vs 9% of patients in the bisoprolol group (adjusted odds ratio, 10.3 [95% CI, 4.0 to 26.6]; P < .001). At 12 months, 8 of 20 outcomes were significantly different (all favoring digoxin), with a median NT-proBNP level of 960 pg/mL (interquartile range, 626 to 1531 pg/mL) in the digoxin group vs 1250 pg/mL (interquartile range, 847 to 1890 pg/mL) in the bisoprolol group (ratio of geometric means, 0.77 [95% CI, 0.64 to 0.92]; P = .005). Adverse events were less common with digoxin; 20 patients (25%) in the digoxin group had at least 1 AE vs 51 patients (64%) in the bisoprolol group (P < .001). There were 29 treatment-related AEs and 16 serious AEs in the digoxin group vs 142 and 37, respectively, in the bisoprolol group. CONCLUSIONS AND RELEVANCE: Among patients with permanent atrial fibrillation and symptoms of heart failure treated with low-dose digoxin or bisoprolol, there was no statistically significant difference in quality of life at 6 months. These findings support potentially basing decisions about treatment on other end points. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02391337 and clinicaltrialsregister.eu Identifier: 2015-005043-13.
引用
- Kotecha D, Bunting KV, Gill SK, et al. Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial. JAMA. 2020. PMID: 33351042. doi:10.1001/jama.2020.23138
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。